Kyprolis (CFZ) Ph1/2 Pediatric ALL
Research payments
$717,435
Through program year 2023, $717,435 in research payments was reported against Kyprolis (CFZ) Ph1/2 Pediatric ALL, across 50 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $30,282 | 5 |
| 2022 | Research | $56,002 | 7 |
| 2021 | Research | $625,101 | 37 |
| 2020 | Research | $6,050 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Margaret Masterson New Brunswick, NJ Named on 5 payments
- Van Huynh Orange, CA Named on 5 payments
- Nobuko Hijiya Memphis, TN Named on 3 payments
- Ashley Hinson Charlotte, NC Named on 3 payments
- Maureen O'Brien Cincinnati, OH Named on 3 payments
- Tamra Slone Dallas, TX Named on 3 payments
- Lia Gore Aurora, CO Named on 2 payments
- Anurag Agrawal Oakland, CA Named on 2 payments
- Michael Burke Milwaukee, WI Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.